A powerful new drug combo has yielded a major breakthrough for men battling an aggressive form of prostate cancer, ...
MedPage Today on MSN
OS Win for Enzalutamide in Prostate Cancer at High Risk for Biochemical Recurrence
BERLIN -- Combining enzalutamide (Xtandi) with androgen deprivation therapy (ADT) significantly improved overall survival (OS ...
Adding the drug enzalutamide to standard hormone therapy reduced deaths by more than 40% in men with recurrent prostate ...
A new drug combo of enzalutamide and hormone therapy has been shown to extend survival for men with recurring prostate cancer ...
The Brighterside of News on MSN
New drug combo cuts risk of death for men with prostate cancer by 40%
Men with recurrent prostate cancer following surgery or radiation therapy may now have a new chance to live longer. A massive ...
A new drug combination to treat advanced recurring prostate cancer has shown remarkable results in a long-term trial, ...
Grape seed extract—a dietary supplement made from the seeds of wine grapes—has been investigated to see if it can help reduce ...
News-Medical.Net on MSN
Breakthrough combo therapy lowers death risk in recurrent prostate cancer
Men whose prostate cancer returns after surgery or radiation therapy may now benefit from a new drug combination shown in clinical trials to cut the risk of death by more than 40%.
Men with prostate cancer that returns after surgery or radiation and are left with few options could benefit from a new ...
A multi-centre study whose leads include London-based researchers has found a new imaging solution that can more effectively ...
A new drug combination cuts the risk of death in people with advanced prostate cancer by 40% over eight years, according to ...
To improve the quality of life of people with cancer, oncologists have regularly recommended exercise. “The thinking in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results